EQL PHARMA AB (7JK) — Capital Reinvestment Ratio
EQL PHARMA AB (7JK) has a Capital Reinvestment Ratio of 0.88x as of December 2025, meaning it reinvests 1% of its operating cash flow (€13.44 Million) in capital expenditures (€11.87 Million). See net asset quality index of EQL PHARMA AB to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
EQL PHARMA AB Capital Reinvestment Ratio (2022–2023)
This chart tracks EQL PHARMA AB's Capital Reinvestment Ratio across 2 annual periods. Check EQL PHARMA AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for EQL PHARMA AB (2022–2023)
Year-by-year Capital Reinvestment Ratio for EQL PHARMA AB from 2022 to 2023. For live market cap and broader valuation context, see market value of EQL PHARMA AB.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.74x | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €41.83 Million | €22.09 Million | — |